- Home
- UPST vs APGE Comparison
UPST vs APGE Comparison
Compare UPST & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UPST | APGE |
|---|---|---|
| Founded | 2012 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 5.0B |
| IPO Year | 2020 | 2023 |
Fundamental Metrics
Financial Performance| Metric | UPST | APGE |
|---|---|---|
| Price | $25.84 | $66.62 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 15 | 11 |
| Target Price | $45.50 | ★ $101.20 |
| AVG Volume (30 Days) | ★ 4.7M | 685.0K |
| Earning Date | 05-05-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 131.25 | N/A |
| EPS | ★ 0.45 | N/A |
| Revenue | ★ $1,043,857,000.00 | N/A |
| Revenue This Year | $33.98 | N/A |
| Revenue Next Year | $32.48 | N/A |
| P/E Ratio | $57.41 | ★ N/A |
| Revenue Growth | ★ 63.99 | N/A |
| 52 Week Low | $25.60 | $26.20 |
| 52 Week High | $85.31 | $84.56 |
Technical Indicators
Market Signals| Indicator | UPST | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 34.90 | 39.60 |
| Support Level | $25.60 | $66.00 |
| Resistance Level | $50.12 | $71.18 |
| Average True Range (ATR) | 1.67 | 3.87 |
| MACD | 0.39 | -0.36 |
| Stochastic Oscillator | 5.91 | 5.35 |
Price Performance
Historical ComparisonAbout UPST Upstart Holdings Inc.
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. Upstart's platform includes personal loans, automotive retail and refinance loans, home equity lines of credit, and small-dollar loans.
About APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.